GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TOT Biopharm International Co Ltd (HKSE:01875) » Definitions » Earnings per Share (Diluted)

TOT Biopharm International Co (HKSE:01875) Earnings per Share (Diluted) : HK$0.05 (TTM As of Dec. 2024)


View and export this data going back to 2019. Start your Free Trial

What is TOT Biopharm International Co Earnings per Share (Diluted)?

TOT Biopharm International Co's Earnings per Share (Diluted) for the six months ended in Dec. 2024 was HK$0.01. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was HK$0.05.

TOT Biopharm International Co's EPS (Basic) for the six months ended in Dec. 2024 was HK$0.01. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2024 was HK$0.05.

TOT Biopharm International Co's EPS without NRI for the six months ended in Dec. 2024 was HK$0.01. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2024 was HK$0.04.

During the past 8 years, TOT Biopharm International Co's highest 3-Year average EPS without NRI Growth Rate was 59.90% per year. The lowest was -39.90% per year. And the median was 24.60% per year.


TOT Biopharm International Co Earnings per Share (Diluted) Historical Data

The historical data trend for TOT Biopharm International Co's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TOT Biopharm International Co Earnings per Share (Diluted) Chart

TOT Biopharm International Co Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Earnings per Share (Diluted)
Get a 7-Day Free Trial -0.61 -0.56 -0.09 -0.06 0.05

TOT Biopharm International Co Semi-Annual Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Earnings per Share (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.06 -0.02 -0.03 0.04 0.01

Competitive Comparison of TOT Biopharm International Co's Earnings per Share (Diluted)

For the Biotechnology subindustry, TOT Biopharm International Co's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TOT Biopharm International Co's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TOT Biopharm International Co's PE Ratio distribution charts can be found below:

* The bar in red indicates where TOT Biopharm International Co's PE Ratio falls into.


;
;

TOT Biopharm International Co Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

TOT Biopharm International Co's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2024 is calculated as

Diluted Earnings Per Share (A: Dec. 2024 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(37.109-0)/725.197
=0.05

TOT Biopharm International Co's Earnings Per Share (Diluted) for the quarter that ended in Dec. 2024 is calculated as

Diluted Earnings Per Share (Q: Dec. 2024 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(3.414-0)/725.197
=0.00

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$0.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


TOT Biopharm International Co  (HKSE:01875) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


TOT Biopharm International Co Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of TOT Biopharm International Co's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


TOT Biopharm International Co Business Description

Traded in Other Exchanges
N/A
Address
120 Changyang Street, Suzhou Industrial Park, Suzhou, CHN, 215024
TOT Biopharm International Co Ltd is a clinical-stage biopharmaceutical company dedicated to developing and commercializing oncology drugs and therapies for patients and their families, as well as medical professionals. The company has a pipeline of oncology drug candidates, which include monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs). The company generates maximum revenues from Mainland China.
Executives
Center Laboratories, Inc. 2201 Interest of corporation controlled by you
Tricor Trust (hong Kong) Limited 2301 Trustee
Chengwei Evergreen Capital, Lp 2101 Beneficial owner
Center Laboratories Inc. 2101 Beneficial owner
Chengwei Evergreen Management, Llc 2201 Interest of corporation controlled by you
Suzhou Vivo Management Consulting Partnership (limited Partnership)
Vivo (suzhou) Health Industry Investment Fund (limited Partnership)
Vivo Capital Llc
Vivo Capital Viii, Llc
Vivo Capital Fund Viii, L.p.
Prime Success International Limited 2101 Beneficial owner
Advantech Capital Ii L.p.
Advantech Capital Ii Master Investment Limited
Advantech Capital Investment V Limited
Advantech Capital Partners Ii Limited

TOT Biopharm International Co Headlines

No Headlines